Replimune Group, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for REPL, updated each market day.
REPL AI Sentiment
AI predicts Replimune Group, Inc. stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Replimune Group, Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Sector
Exchange
Market Cap
$488,004,178
Cap Tier
Employees
479
Headquarters
WOBURN, MA
Listed Since
July 20, 2018
Website
REPL Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
REPL Volatility
Replimune Group, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
